Annals of Surgical Oncology, Vol 5, Issue 8 673-680, Copyright © 1998 by Society of Surgical Oncology

ARTICLES

Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer

H. M. Kuerer, L. A. Newman, B. D. Fornage, K. Dhingra, K. K. Hunt, A. U. Buzdar, F. C. Ames, M. I. Ross, B. W. Feig, G. N. Hortobagyi and S. E. Singletary
Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston 77030, USA.

BACKGROUND: Induction chemotherapy has become the standard of care for patients with locally advanced breast cancer (LABC) and currently is being evaluated in prospective clinical trials in patients with earlier-stage disease. To better gauge the role of axillary lymph node dissection in patients with LABC this study was performed to assess initial axillary status on physical and ultrasound examination, axillary tumor downstaging following induction chemotherapy, and the accuracy of physical examination compared with axillary sonography in predicting which patients will have axillary lymph node metastases found on pathologic examination. METHODS: Between 1992 and 1996, 147 consecutive patients with LABC were registered in a prospective trial of induction chemotherapy using 5-fluorouracil, doxorubicin, and cyclophosphamide. Physical and ultrasound examinations of the axilla were performed at diagnosis and after induction chemotherapy. Segmental resection with axillary lymph node dissection or modified radical mastectomy was performed, followed by postoperative chemotherapy and irradiation of the breast or chest wall and regional lymphatics. RESULTS: Following induction chemotherapy, 43 (32%) of the 133 patients with clinically positive lymph nodes on initial examination had axillary tumor downstaging as assessed by physical and ultrasound examination. The sensitivity of axillary sonography in identifying axillary metastases was significantly higher than that of physical examination (62% vs. 45%, P=.012). The specificity of physical examination (84%) was higher than that of sonography (70%), but the difference did not reach statistical significance. Among the 55 patients in whom the findings of both physical and ultrasound examination of the axilla were negative following induction chemotherapy, 29 patients (53%) were found to have axillary lymph node metastases on pathologic examination of the axillary contents. However, 28 (97%) of these patients had either 1 to 3 positive lymph nodes or only micrometastases 2 to 5 mm in diameter. CONCLUSIONS: Preoperative clinical assessment of the axilla by physical examination combined with ultrasound examination is not completely accurate in predicting metastases in patients with LABC following tumor downstaging. However, patients with negative findings on both physical and ultrasound examinations of the axilla may be potential candidates for omission of axillary dissection if the axilla will be irradiated because minimal axillary disease remains. Patients who have positive findings on preoperative physical or ultrasound examinations should receive axillary dissection to ensure local control. A prospective randomized trial of axillary dissection versus axillary radiotherapy in patients with a clinically negative axilla following induction chemotherapy is currently underway.

This article has been cited by other articles:

				S. Chia, S. M. Swain, D. R. Byrd, and D. A. Mankoff Locally Advanced and Inflammatory Breast Cancer J. Clin. Oncol., February 10, 2008; 26(5): 786 - 790. [Full Text] [PDF]

				J.-C. Yu, G.-C. Hsu, C.-B. Hsieh, C.-P. Yu, and T.-Y. Chao Role of Sentinel Lymphadenectomy Combined with Intraoperative Ultrasound in the Assessment of Locally Advanced Breast Cancer After Neoadjuvant Chemotherapy Ann. Surg. Oncol., January 1, 2007; 14(1): 174 - 180. [Abstract] [Full Text] [PDF]

				P. F. Escobar, R. J. Patrick, L. A. Rybicki, D. Hicks, D. E. Weng, and J. P. Crowe Prognostic Significance of Residual Breast Disease and Axillary Node Involvement for Patients Who Had Primary Induction Chemotherapy for Advanced Breast Cancer Ann. Surg. Oncol., June 1, 2006; 13(6): 783 - 787. [Abstract] [Full Text] [PDF]

				B. T. Hennessy, G. N. Hortobagyi, R. Rouzier, H. Kuerer, N. Sneige, A. U. Buzdar, S. W. Kau, B. Fornage, A. Sahin, K. Broglio, et al. Outcome After Pathologic Complete Eradication of Cytologically Proven Breast Cancer Axillary Node Metastases Following Primary Chemotherapy J. Clin. Oncol., December 20, 2005; 23(36): 9304 - 9311. [Abstract] [Full Text] [PDF]

				A. C. Wolff and N. E. Davidson Preoperative Therapy in Breast Cancer: Lessons from the Treatment of Locally Advanced Disease Oncologist, June 1, 2002; 7(3): 239 - 245. [Abstract] [Full Text] [PDF]

				I. C. Smith, S. D. Heys, A. W. Hutcheon, I. D. Miller, S. Payne, F. J. Gilbert, A. K. Ah-See, O. Eremin, L. G. Walker, T. K. Sarkar, et al. Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel J. Clin. Oncol., March 15, 2002; 20(6): 1456 - 1466. [Abstract] [Full Text] [PDF]

				R. Rouzier, J.-M. Extra, J. Klijanienko, M.-C. Falcou, B. Asselain, A. Vincent-Salomon, P. Vielh, and E. Bourstyn Incidence and Prognostic Significance of Complete Axillary Downstaging After Primary Chemotherapy in Breast Cancer Patients With T1 to T3 Tumors and Cytologically Proven Axillary Metastatic Lymph Nodes J. Clin. Oncol., March 1, 2002; 20(5): 1304 - 1310. [Abstract] [Full Text] [PDF]

				M. H. Chung, W. Ye, and A. E. Giuliano Role for Sentinel Lymph Node Dissection in the Management of Large (>=5 cm) Invasive Breast Cancer Ann. Surg. Oncol., October 1, 2001; 8(9): 688 - 692. [Abstract] [Full Text] [PDF]

				L. Esserman, E. Kaplan, S. Partridge, D. Tripathy, H. Rugo, J. Park, S. Hwang, H. Kuerer, D. Sudilovsky, Y. Lu, et al. MRI Phenotype Is Associated With Response to Doxorubicin and Cyclophosphamide Neoadjuvant Chemotherapy in Stage III Breast Cancer Ann. Surg. Oncol., July 1, 2001; 8(6): 549 - 559. [Abstract] [Full Text] [PDF]